Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials

References

• World Health Organization. Liver; [ cited 2021 Oct 26].
   Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. •• The phase 3 trial demonstrating the efficacy and safety of cabozantinib as a second and third-line option for advanced hepatocellular carcinoma.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952.
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn, RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v875–v934.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J Clin Oncol. 2020;38(3):193–202.
   PubMed Web of Science ®Google Scholar
• Merck announces KEYTRUDA (pembrolizumab) met primary endpoint of overall survival (OS) in patients with advanced hepatocellular carcinoma previously treated with sorafenib. News release. Merck; 2021 Sep 27 [cited 2021 Oct 28].
   Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. •• The phase 3 trial proving the superiority of atezolizumab plus bevacizumab over sorafenib, thus establishing a new standard of care for first-line treatment.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Masafumi I, et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267.
   Web of Science ®Google Scholar
• Llovet JM, Kudo M, Cheng A-L, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J Clin Oncol. 2019;37(15_suppl): TPS4152–TPS415216.
   Web of Science ®Google Scholar
• Kelley RK, Oliver JW, Hazra S, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 phase III study design. Future Oncol. 2020;16(21):1525–1536.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Furuse J, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J Clin Oncol. 2018;36: TPS4144–TPS4144.
   PubMed Web of Science ®Google Scholar
• A study of nivolumab in combination with ipilimumab in participants with advanced hepatocellular carcinoma (CheckMate 9DW). [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04039607
   Google Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–1239.e1224.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park J-W, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–3524.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans T, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2014;33(6):559–566.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–693.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Morse MA, Sun W, Kim R, et al. The Role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912–920.
   PubMed Web of Science ®Google Scholar
• Amini A, Masoumi Moghaddam S, Morris DL, et al. The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets. 2012;12(1):23–43.
   PubMed Web of Science ®Google Scholar
• Personeni N, Pressiani T, Bozzarelli S, et al. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol. 2019;11(10):788–803.
   PubMed Web of Science ®Google Scholar
• D’Alessio A, Cammarota A, Prete MG, et al. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol. 2021;33(4):386–394.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Pressiani T, Personeni N, et al. Regorafenib for the treatment of unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17(7):567–576.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Debelius J, Brenner DA, et al. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411.
   PubMed Web of Science ®Google Scholar
• Iñarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res. 2018;24(7):1518–1524.
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, et al. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–1429.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88.
   PubMed Web of Science ®Google Scholar
• Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.
   PubMedGoogle Scholar
• Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72(2):342–352.
   PubMed Web of Science ®Google Scholar
• Singleton DC, Macann A, and Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol. 2021;18 (12):751-772.
   PubMed Web of Science ®Google Scholar
• Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250–254.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhu X-D, Sun H-C, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010;16(13):3420–3430.
   PubMed Web of Science ®Google Scholar
• Iyer RV, Maguire O, Kim M, et al. Dose-dependent sorafenib-induced immunosuppression is associated with aberrant NFAT activation and expression of PD-1 in T cells. Cancers (Basel). 2019;11(5):681.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307–319. • A review encompassing the role of combination treatment strategies for hepatocellular carcinoma, trying to delineate the future of precision medicine for this disease.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLOS ONE. 2019;14(2):e0212513.
   PubMed Web of Science ®Google Scholar
• Shigeta K, Matsui A, Kikuchi H, et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020;8(2):e001435.
   PubMed Web of Science ®Google Scholar
• Esteban-Fabró R, Willoughby CE, and Piqué-Gili M, et al. O-02 Cabozantinib enhances anti-PD1 efficacy and elicits a neutrophil-based immune response in murine models: implications for human HCC. ILCA Annual conference - Book of Abstracts Virtual Conference; 2021; p. 5.
   Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12:294.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ikeda M, Motomura K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): study 117. J Clin Oncol. 2020;38(suppl_4):513.
   Web of Science ®Google Scholar
• Galle PR, Kim R, Sung MW, et al. 990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Ann Oncol. 2020;31:S691–S692.
   Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Yau T, Zagonel V, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol. 2020;38(suppl_4):478.
   Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20(11):2959–2970.
   PubMed Web of Science ®Google Scholar
• Bergerot P, Lamb P, Wang E, et al. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18(12):2185–2193.
   PubMed Web of Science ®Google Scholar
• Lacy SA, Miles DR, Nguyen LT. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. Clin Pharmacokinet. 2017;56(5):477–491.
   PubMed Web of Science ®Google Scholar
• Cabometyx summary of product characteristics.
   Google Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307–314.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122.
   PubMed Web of Science ®Google Scholar
• Centanni M, Moes DJAR, Trocóniz IF, et al. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58(7):835–857.
   PubMed Web of Science ®Google Scholar
• Stroh M, Winter H, Marchand M, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102(2):305–312.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–88.
   PubMed Web of Science ®Google Scholar
• Study of cabozantinib in combination with atezolizumab to subjects with locally advanced or metastatic solid tumors. [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT03170960
   Google Scholar
• Pal SK, McGregor B, Suarez C, et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 Study. J Clin Oncol. 2021;39(33):3725–3736. • The phase 1b trial demonstrating safety and efficacy of cabozantinib + atezolizumab in renal cell carcinoma.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Vaishampayan UN, Green M, et al. Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC). Ann Oncol. 2018;29(suppl_8):viii303–viii331.
   Google Scholar
• Pal SK, Tsao C, Suarez C, et al. Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from the COSMIC-021 study. Ann Oncol. 2020;31(suppl_4):S550–S550.
   Google Scholar
• A study of atezolizumab in combination with cabozantinib compared to cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment. [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04338269
   Google Scholar
• Pal SK, Agarwal N, Loriot Y, et al. Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: results from cohort 2 of the COSMIC-021 study. J Clin Oncol. 2020;38(suppl_15):5013.
   Google Scholar
• Neal JW, Lim FL, Felip E, et al. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study. J Clin Oncol. 2020;38(suppl_15):9610. Poster 376.
   Web of Science ®Google Scholar
• Agarwal N, McGregor B, Maughan BL, et al. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of expanded cohort 6 of the COSMIC-021 study. Ann Oncol. 2021;32(suppl_5):S1283–S1346.
   Google Scholar
• Study of atezolizumab in combination with cabozantinib versus docetaxel in patients with metastatic non-small lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy (CONTACT-01). [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04471428
   Google Scholar
• Study of cabozantinib in combination with atezolizumab versus second NHT in subjects with mCRPC. [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04446117
   Google Scholar
• Kelley RK, Yau T, and Cheng A-L, et al. Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. ESMO Asia Virtual Oncol Week. 2021 : Abstract VP10–2021. [cited 20 November 2021]. •• Results of the ongoing phase 3 trial investigating cabozantinib plus atezolizumab against sorafenib as a front-line option for hepatocellular carcinoma.
   Google Scholar
• Exelixis announces detailed results from Phase 3 COSMIC-312 pivotal trial of cabozantinib in combination with an immune checkpoint inhibitor in patients with previously untreated advanced liver cancer at ESMO Asia Virtual Oncology Week 2021. [ cited 2021 Dec 24].
   Google Scholar
• Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer. News release. AstraZeneca; 2021 Oct 15 [cited 2021 Nov 1]. https://bit.ly/3vgpAVB
   Google Scholar
• Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001.
   PubMed Web of Science ®Google Scholar
• Scirocchi F, Napoletano C, Pace A, et al. Immunogenic cell death and immunomodulatory effects of cabozantinib. Front Oncol. 2021;11(20):755433.
   PubMedGoogle Scholar
• Singal AG, Hoshida Y, Pinato DJ, et al. International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021;160(7):2572–2584.
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–829.
   PubMed Web of Science ®Google Scholar
• Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456. •• A key translational work highlighting the mechanisms suggesting the lack of response of NASH-related HCC to immunotherapy.
   PubMed Web of Science ®Google Scholar
• Haber PK, Puigvehí M, Castet F, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology. 2021;161(3):879–898.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Marron TU, Mishra-Kalyani PS, et al. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021;157:140–152.
   PubMed Web of Science ®Google Scholar
• Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61(2):318–324.
   PubMed Web of Science ®Google Scholar
• Bruix J, Merle P, Granito A, et al. Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. J Clin Oncol. 2018;36(suppl_4):412.
   Web of Science ®Google Scholar
• Sung MW, Finn RS, Qin S, et al. Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT). J Clin Oncol. 2019;37(suppl_4):317.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial. J Clin Oncol. 2019;37(suppl_15):4088.
   Web of Science ®Google Scholar
• Yoo C, Kim JH, Ryu MH, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer. 2021;10:107–114.
   PubMed Web of Science ®Google Scholar
• A study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with atezolizumab and bevacizumab (IMbrave251). [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04770896
   Google Scholar
• Regorafenib plus pembrolizumab in patients with advanced or spreading liver cancer who have been previously treated with PD-1/PD-L1 immune checkpoint inhibitors. [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04696055.
   Google Scholar
• Efficacy and safety of cabozantinib in patients with hepatocellular carcinoma (Immunocabo). [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT04435977
   Google Scholar
• Alsina A, Kudo M, Vogel A, et al. Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. Liver Cancer. 2020;9:93–104.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ryoo BY, Merle P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020;5:e000714.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology. 2021;73(suppl_1):158–191. • A position paper discussing the current limits and the future directions of trial design and endpoints definition in hepatocellular carcinoma.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Villanueva A. Randomized trials and end-points in advanced HCC: role of PFS as a surrogate of survival. J Hepatol. 2019;70:1262–1277.
   PubMed Web of Science ®Google Scholar
• Nivolumab plus ipilimumab as neoadjuvant therapy for hepatocellular carcinoma (HCC). [cited 20 November 2021]. https://ClinicalTrials.gov/show/NCT03510871
   Google Scholar
• Safety and bioactivity of ipilimumab and nivolumab combination prior to liver resection in hepatocellular carcinoma. [cited 20 November 20]. https://ClinicalTrials.gov/show/NCT03682276
   Google Scholar
• Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16(15):975–989.
   PubMed Web of Science ®Google Scholar
• Flynn MJ, Sayed AA, Sharma R, et al. Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma. Hepatology. 2019;69(5):2258–2270.
   PubMed Web of Science ®Google Scholar
• Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2:891–903.
   PubMedGoogle Scholar